Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Immunology Pavlos > Clinical and Pathological Features of Immune-Mediated Inflammatory Diseases and Approved Treatments > Flashcards

Clinical and Pathological Features of Immune-Mediated Inflammatory Diseases and Approved Treatments Flashcards

(60 cards)

Start Studying
1
Q

Genetic characteristics RA

A

• MHC class II (DR4)
• PTPN22, CTLA4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Conventional anchor drug
RA

A

MTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Genetic characteristics CD

A

• MHC class II (DRB1)
• Interleukin-23R, NOD2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Conventional anchor drug
CD

A

AZT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Conventional anchor drug
UC

A

Cyclosporin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Genetic characteristics UC

A

• MHC class II (DRB1)
• Interleukin-23R, interleukin-10R

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Genetic characteristics Axial spondylarthritis

A

• MHC class I (B27)
• Interleukin-23R, ERAP1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Conventional anchor drug
Axial spondylarthritis

A

Sulfasalazin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Genetic characteristics psoriatic arthritis

A

• MHC class I (C06)
• Interleukin-23R, A20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Conventional anchor drug
psoriatic arthritis

A

MTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Drivers RA

A

Autoimmunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Drivers CD

A

Microbial dysbiosis and barrier dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Drivers UC

A

Microbial dysbiosis and barrier dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Drivers axial spondylarthritis

A

Mechanical stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Drivers psoriatic arthritis

A

Mechanical stress and metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Key pathological process RA

A

Synovitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Key pathological process
CD

A

Granuloma formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Key pathological process UC

A

Cryptitis and goblet-cell loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Key pathological process
Axial spondylarthritis

A

Axial enthesitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Key pathological process
Psoriatic arthritis

A

Enthesitis and synovitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Key associated disease RA

A

Interstitial lung disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Key associated disease CD

A

Erythema nodosum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Key associated disease UC

A

PSC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Key associated disease Axial Spondyloarthritis

A

Anterior uveitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Key associated disease Psoriatic arthritis
Psoriasis
26
NSAID responsiveness RA
Absent
27
Glucocorticoid responsiveness RA
High
28
NSAID responsiveness CD
Absent
29
Glucocorticoid responsiveness CD
high
30
NSAID responsiveness UC
Absent
31
Glucocorticoid responsiveness UC
high
32
NSAID responsiveness Axial spondylarthritis
High
33
Glucocorticoid responsiveness Axial spondylarthritis
Absent
34
NSAID responsiveness psoriatic arthritis
Moderate
35
Glucocorticoid responsiveness psoriatic arthritis
Moderate
36
Cellular immune response RA
B cells, Tph or Tfh cells, macrophages, fibroblasts
37
Cellular immune response CD
Th1/Th17 cells, dendritic cells, macrophages
38
Cellular immune response UC
Th2/Th9/Th17 cells, neutrophils
39
Cellular immune response axial spondylarthritis
Th17 cells, T γ/δ cells, ILC3, neutrophils
40
Cellular immune response psoriatic arthritis
Th17 cells, T γ/δ cells, ILC3, neutrophils, fibroblasts
41
Approved TNF-α inhibitors RA
Adalimumab, certolizumab, etanercept, golimumab, infliximab
42
Approved TNF-α inhibitors CD
Adalimumab, certolizumab (U.S.), infliximab
43
Approved TNF-α inhibitors UC
Adalimumab, certolizumab (U.S.), golimumab, infliximab
44
Approved TNF-α inhibitors Axial spondylarthritis
Adalimumab, certolizumab, etanercept, golimumab, infliximab
45
Approved TNF-α inhibitors psoriatic arthritis
Adalimumab, certolizumab, etanercept, golimumab, infliximab
46
Approved cytokine signature drugs (targets) RA
Tocilizumab (IL-6R), sarilumab (IL-6R)
47
Approved cytokine signature drugs (targets) CD
Ustekinumab (IL-12/23)
48
Approved cytokine signature drugs (targets) UC
Ustekinumab (IL-12/23)
49
Approved cytokine signature drugs (targets) Axial spondylathtitis
Secukinumab (IL-17A), ixekizumab (IL-17A)
50
Approved cytokine signature drugs (targets) psoriatic arthritis
Secukinumab (interleukin-17A), ixekizumab (IL-17A), ustekinumab (IL-12/23), guselkumab (p19, IL-23)
51
Other approved targeted therapies RA
Abatacept, rituximab
52
Other approved targeted therapies CD
Vedolizumab
53
Other approved targeted therapies UC
Vedolizumab
54
Other approved targeted therapies axial spondylathritis
None
55
Other approved targeted therapies psoriatic arthritis
Apremilast, abatacept
56
Approved JAK inhibitors RA
Tofacitinib, baricitinib, upadacitinib, filgotinib (E.U.)
57
Approved JAK inhibitors CD
None
58
Approved JAK inhibitors UC
Tofacitinib
59
Approved JAK inhibitors axial spondylarthritis
Upadacitinib (E.U.)
60
Approved JAK inhibitors psoriatic arthritis
Tofacitinib, upadacitinib (E.U.)

Immunology Pavlos (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions